<DOC>
	<DOCNO>NCT02231905</DOCNO>
	<brief_summary>Study ass safety , tolerability effectiveness switch Domin® ( talipexole ) tablet BI Sifrol® ( pramipexole ) tablet patient Parkinson 's disease</brief_summary>
	<brief_title>Safety , Tolerability Efficacy Switching From Talipexole Pramipexole Patients With Parkinson 's Disease</brief_title>
	<detailed_description />
	<mesh_term>Parkinson Disease</mesh_term>
	<mesh_term>Pramipexole</mesh_term>
	<mesh_term>Talipexole</mesh_term>
	<criteria>1 . Diagnosis Parkinson 's disease ( include juvenile parkinsonism ) treat talipexole ( Domin® ) 2 . Patients present stable symptom maintain dos talipexole concomitant therapy Parkinson 's disease least last 4 week 3 . Male female patient age 20 4 . In outpatient 5 . Patient 's severity characterize Stage 1 5 Modified Hoehn &amp; Yahr scale 6 . Ability provide write informed consent accordance Good Clinical Practice ( GCP ) , Good Postmarketing Surveillance Practice ( GPMSP ) relevant law Pharmaceutical Affairs Law 1 . History hypersensitivity pramipexole 2 . Psychiatric symptoms confusion , hallucination , delusion , agitation , delirium abnormal behavior 3 . Subjective symptom derive orthostatic hypotension 4 . Hypotension ( systolic blood pressure ; 100 mmHg less ) 5 . Complication clinically significant cardiac , renal hepatic disease 6 . Patients drive car , operate machine , work height engage hazardous activity 7 . Pregnant , possibly pregnant female lactation 8 . Patients participate drug study receive investigational drug within last 3 month enrol study 9 . Other , judged investigator subinvestigator inappropriate study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2014</verification_date>
</DOC>